Preparing healthcare companies for success
in the value-based economy

New Access Meter Report
NOW AVAILABLE

more info >

Solutions

Real Endpoints brings a wide range of strategic and operational market access solutions to our clients.

more >

Insights

Real Endpoints is a thought leader within the pharmaceutical industry. We actively publish and lead panels and are frequently quoted in the press.

more >

Our Solutions

Value-Based Dealmaker

Design and orchestrate value-based deals

RxScorecardTM

Guide strategic and development decisions with customized, interactive value framework

Access Meter

Defining payer challenges for emerging drugs with a validated database

Hub ExcellenceTM

Maximize the impact of patient services programs via benchmarking and needs analysis

Reimbursement iQTM

Enhance impact of customer-facing representatives using 360˚analysis

Customer Gateway

Develop customized program to foster goodwill with customers

Communications
and Training

Address customer pain points with targeted materials; strengthen confidence and knowledge of reps via customized training

Advisory and
Market Research

Generate strategic recommendations — conduct qualitative and quantitative research

News and Events

Gene Therapies Force Payment Innovation

by Gina Shaw

As effective as new gene therapy treatments may be, high setup costs, variable clinical responses, and issues with reimbursement and coding have resulted in significant losses for some manufacturers and providers. “The one-time administration for these therapies introduces a mismatch with benefits” said Jane F. Barlow, Real Endpoints Chief Clinical Officer. “The cost is front-loaded, but benefits accrue over time, creating a challenge as patients move in and out of plans. This is very different than what we see with chronic medications.”

May 17, 2019

Pharmacy Technology Report

read full article >

NewYorkBio 2019 Annual Meeting

Panelist: Jeff Berkowitz

Real Endpoints

PANEL DISCUSSION I: Impact of Pricing and Policy on the Next Decade of Therapeutic Innovation

May 14, 2019
9:30am ET

Financial District, New York, NY

event >

Paying for Pharmaceutical Value: The Problem of a One-Size-Fits-All Definition

by Roger Longman

The industry has plenty of ways to define value. Thousands of academic and corporate health economists busily grind out cost-effectiveness analyses. CMS has designated five "compendia" as guides for reimbursable value, despite bizarrely opaque decision-making behind the compendias' choices.

April 12, 2019

In Vivo

news >

Recent Insights

view archive >

June 11, 2019

Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies?

Access to new gene therapies may be impacted by payer ability to absorb the cost of coverage. Payers are open to innovative financing models that improve financial predictability and reward clinical performance.

read full insight article >

February 13, 2019

Examining New Payment Ideas for Curative Therapies

How can the health industry ensure that cutting-edge gene therapies and other curative treatments get to the patients that need them, without leaving payers financially exposed? Jane F. Barlow, MD, MPH, MBA, was a speaker at the FoCUS (Financing and Reimbursement of Cure in US) Project at MIT, during the session "Putting Theory into Practice" she was quoted saying the “accessibility issue lies largely with payers.” All payers are different, and “a lot has to do with how they manage risk in their population as well as the regulatory constraints."

read full insight article >
Just a quick note of appreciation for your responsiveness throughout the Market Access training process.  Your follow-up on a range of issues was always immediate and the resolution was definitive.  That type of effort and support doesn’t go unnoticed by me.

National Business Director

Top 5 Pharma

We have never seen a diagnostic like this before – it gets right to the heart of the problem.

Senior Director

Specialty Access Solutions, Top 5 Pharma

The insights you provided via Hub Excellence were the most insightful and actionable market research I have ever received.

Director of Operations

Reimbursement and Patient Support Services, Top 20 Pharma

RxScorecard provides a comprehensive, multi-pronged rubric assisting us in decision-making as we begin to move from a volume to value drug evaluation methodology.

Chronis H. Manolis, RPh

Vice President, Pharmacy UPMC Health Plan

We at GSK believe that it’s critical for the pharmaceutical industry to produce drugs that deliver value for patients, providers and payers. We have found RxScorecard to be an insightful framework for assessing and comparing the value of drugs, both marketed and developmental assets. The perspective it provides supports improved customer-focused development and commercialization, and we and our customers can benefit from its use.

Jack Bailey

President , GlaxoSmithKline U.S.